Drugs / PrevinC
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 4 | NCT02225912 | Feb → May 2005 | respiratory tract infectious disorder | BioHealth Technologies Inc. | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | PrevinC | “The hypothesis was to establish whether the use of PrevinC administered nasally 2-3 times a day will prevent upper respiratory infections in otherwise healthy adults working in...” NCT02225912 ↗ |
| Route | Intranasal | “PrevinC administered nasally 2-3 times a day” NCT02225912 ↗ |